시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
세계의 비대형 심근증 치료 시장 보고서(2025년)
Hypertrophic Cardiomyopathy Treatment Global Market Report 2025
상품코드 : 1825418
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 250 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,498,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,393,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 12,288,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

비대형 심근증 치료 시장 규모는 향후 수년간 안정된 성장이 전망됩니다. 2029년에는 17억 달러로 성장하며, CAGR은 4.8%에 달합니다. 예측 기간의 성장은 표적치료, 원격의료 및 원격 모니터링, 맞춤형 의료, 재생의료에 기인합니다. 예측 기간의 주요 동향으로는 조기 개입, 환자 중심 치료, 웨어러블 의료 기술, 건강 형평성 노력 등이 있습니다.

향후 5년간 4.8%의 성장률 전망은 지난번 전망치보다 0.1% 소폭 하락한 수치입니다. 이 감소는 주로 미국과 다른 국가 간의 관세의 영향에 기인합니다. 무역 마찰은 네덜란드와 일본에서 개발된 중격 축소 장치와 유전자 검사 키트의 가격을 급등시켜 증상 관리의 장기화와 전문 의료비 상승을 초래하여 미국의 첨단 비대성 심근증(HCM) 치료법의 채택을 방해할 수 있습니다. 또한 상호 관세와 무역 긴장과 제한 증가로 인한 세계 경제와 무역에 대한 악영향으로 인해 그 영향은 더욱 광범위하게 나타날 것으로 보입니다.

비만율 증가는 당분간 비대성 심근증 치료제 시장 확대의 촉매제로 작용할 것으로 예측됩니다. 비만은 건강에 해로운 영향을 미치는 과도한 체지방의 비정상적인 축적을 특징으로 합니다. 많은 경우, 섭취 칼로리와 신체 활동으로 인한 칼로리 소모의 불균형에서 비롯됩니다. 특히 비만은 비대성 심근증(HCM)에서 흔히 나타나며, 그 표현형에 영향을 미치는 것으로 알려져 있습니다. 예를 들어 2022년 3월 세계보건기구(WHO)는 비만이 전 세계에서 10억 명 이상에게 영향을 미치고 있으며, 그 중 성인 6억 5,000만 명, 청소년 3억 4,000만 명, 소아 3,900만 명이 비만이라는 보고서를 발표했습니다. 또한 2025년까지 1억 6,700만 명이 과체중과 비만으로 인한 건강 문제에 직면할 것으로 예측됩니다. 그 결과, 비만율 증가는 비대성 심근증 치료제 시장의 원동력이 될 것으로 예측됩니다.

목차

제1장 개요

제2장 시장의 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세 및 Covid와 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별·국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 개요

제31장 기타 대기업과 혁신적 기업

제32장 세계의 시장 경쟁 벤치마킹과 대시보드

제33장 주요 합병과 인수

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

제36장 부록

KSA
영문 목차

영문목차

Hypertrophic cardiomyopathy (HCM) is a heart condition characterized by the thickening of the heart muscle, primarily affecting the left ventricle, the major pumping chamber. This thickening often occurs at the septum, which is the muscular wall separating the left and right sides of the heart. The treatment approach for hypertrophic cardiomyopathy is personalized, and specific recommendations can vary depending on individual cases.

The primary categories of hypertrophic cardiomyopathy treatment include obstructive hypertrophic cardiomyopathy treatment and non-obstructive hypertrophic cardiomyopathy treatment. Obstructive hypertrophic cardiomyopathy (HCM) is a condition in which the thickening of the muscular wall (septum) between the two lower chambers of the heart (ventricles) can block the flow of blood out of the heart. Diagnosis of hypertrophic cardiomyopathy involves various tests, including chest X-rays, echocardiograms, electrocardiograms (ECGs), treadmill stress tests, cardiac catheterization, genetic testing or screening, cardiac MRI, cardiac CT scans, and blood tests. Treatment can take various forms, such as medication, surgically implanted devices, nonsurgical procedures, and surgery. These treatments are applied in various healthcare settings, including hospitals, research institutes, and specialty clinics.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The hypertrophic cardiomyopathy treatment market research report is one of a series of new reports from The Business Research Company that provides hypertrophic cardiomyopathy treatment market statistics, including hypertrophic cardiomyopathy treatment industry global market size, regional shares, competitors with a hypertrophic cardiomyopathy treatment market share, detailed hypertrophic cardiomyopathy treatment market segments, market trends and opportunities and any further data you may need to thrive in the hypertrophic cardiomyopathy treatment industry. This hypertrophic cardiomyopathy treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The hypertrophic cardiomyopathy treatment market size has grown steadily in recent years. It will grow from $1.37 billion in 2024 to $1.41 billion in 2025 at a compound annual growth rate (CAGR) of 3.2%. The growth in the historic period can be attributed to advances in diagnostic technologies, drug therapies, surgical interventions, clinical guidelines.

The hypertrophic cardiomyopathy treatment market size is expected to see steady growth in the next few years. It will grow to $1.7 billion in 2029 at a compound annual growth rate (CAGR) of 4.8%. The growth in the forecast period can be attributed to targeted therapies, telemedicine and remote monitoring, personalized medicine, regenerative medicine. Major trends in the forecast period include early intervention, patient-centered care, wearable health technology, health equity initiatives.

The forecast of 4.8% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Trade tensions could hinder U.S. adoption of advanced Hypertrophic Cardiomyopathy(HCM) therapies by inflating prices of septal reduction devices and genetic testing kits developed in the Netherlands and Japan, resulting in prolonged symptom management and higher specialty care costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The growth in obesity rates is anticipated to act as a catalyst for the expansion of the hypertrophic cardiomyopathy treatment market in the foreseeable future. Obesity is characterized by an abnormal accumulation of excess body fat that can have detrimental effects on one's health. It often results from an imbalance between calorie intake and expenditure through physical activity. Notably, obesity is a common occurrence in individuals with hypertrophic cardiomyopathy (HCM) and is believed to influence the phenotype of the condition. For instance, in March 2022, the World Health Organization released a report indicating that obesity affects over one billion individuals worldwide, encompassing 650 million adults, 340 million adolescents, and 39 million children. Furthermore, it is projected that by 2025, an additional 167 million people will face health challenges associated with being overweight or obese. Consequently, the upsurge in obesity rates is poised to be a driving force behind the hypertrophic cardiomyopathy treatment market.

Rising patient awareness and education programs are expected to drive the growth of the hypertrophic cardiomyopathy (HCM) treatment market in the coming years. These programs aim to influence patient behavior by improving understanding, mindset, and skills necessary to maintain or improve health through the provision of crucial information. Hypertrophic cardiomyopathy is a rare genetic disorder that often goes undiagnosed due to a lack of awareness. The launch of awareness and education programs for this disease helps reduce risks by promoting early diagnosis and treatment. For example, in September 2024, GOV.UK reported a 0.9% increase in adult participation in further education and skills in the UK, with 1,627,320 participants. Moreover, participation in adult education and training rose by 4.6%, reaching 863,790. Therefore, the growing emphasis on patient awareness and education is propelling the hypertrophic cardiomyopathy treatment market.

Market players operating in the hypertrophic cardiomyopathy treatment domain are actively engaged in pioneering drug development endeavors to uphold their standing within the market. This pursuit of drug development and innovation serves to advance our understanding of disease mechanisms and accelerate the emergence of novel treatment modalities. A case in point is the announcement made by Bristol Myers Squibb Co. in April 2022, whereby the US Food and Drug Administration (FDA) granted approval for Camzyos (mavacamten), designed for the treatment of individuals exhibiting symptoms of obstructive hypertrophic cardiomyopathy (obstructive HCM) classified under New York Heart Association (NYHA) class II-III. Camzyos represents a groundbreaking allosteric and reversible cardiac myosin inhibitor engineered to address the underlying pathology of obstructive HCM. With this green light from the FDA, cardiologists in the United States now have access to a new pharmaceutical option for eligible patients, offering a therapeutic approach that directly targets the fundamental pathophysiology of the disease.

In March 2023, Viz.ai, in collaboration with Bristol-Myers Squibb Company, embarked on an endeavor to detect and triage patients requiring further evaluation for hypertrophic cardiomyopathy (HCM) detection through the utilization of an artificial intelligence (AI) algorithm and the Viz HCM provider workflow software. This partnership between Viz and Bristol Myers Squibb seeks to ensure that underdiagnosed and underserved HCM patients receive the necessary care promptly, courtesy of proficient healthcare providers. The comprehensive offering includes a mobile-based ECG viewer, AI-based alerts for timely intervention, and communication capabilities designed to enhance cardiac care coordination. Bristol Myers Squibb Co. is a pharmaceutical enterprise headquartered in the United States that specializes in the treatment of hypertrophic cardiomyopathy (HCM).

Major companies operating in the hypertrophic cardiomyopathy treatment market are Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Abbott Laboratories Ltd., GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., Teva Pharmaceutical Industries Ltd., Boston Scientific Corporation, Mylan N.V., Sun Pharmaceutical Industries Ltd., PerkinElmer Inc., Cipla Ltd., Aurobindo Pharma Ltd., Bio-Rad Laboratories Inc., Covance Laboratories Ltd., Hikma Pharmaceuticals PLC, Endo International Inc., Lupin Limited, Zydus Lifesciences Limited, XyloCor Therapeutics Inc., Cytokinetics Inc., Santhera Pharmaceuticals Holding AG, DiNAQOR AG, Correvio Pharma Corp, Cardurion Pharmaceuticals Inc.

North America was the largest region in the hypertrophic cardiomyopathy treatment market in 2024. The regions covered in hypertrophic cardiomyopathy treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the hypertrophic cardiomyopathy treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, and Spain.

The hypertrophic cardiomyopathy treatment market consists of revenues earned by entities by providing services such as surgical myectomy, implantable defibrillator and septal alcohol ablation therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The hypertrophic cardiomyopathy market also includes the sales of medications such as calcium channel blockers, heart rhythm drugs and blood thinners. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Hypertrophic Cardiomyopathy Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on hypertrophic cardiomyopathy treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for hypertrophic cardiomyopathy treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The hypertrophic cardiomyopathy treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Scope

Table of Contents

1. Executive Summary

2. Hypertrophic Cardiomyopathy Treatment Market Characteristics

3. Hypertrophic Cardiomyopathy Treatment Market Trends And Strategies

4. Hypertrophic Cardiomyopathy Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Hypertrophic Cardiomyopathy Treatment Growth Analysis And Strategic Analysis Framework

6. Hypertrophic Cardiomyopathy Treatment Market Segmentation

7. Hypertrophic Cardiomyopathy Treatment Market Regional And Country Analysis

8. Asia-Pacific Hypertrophic Cardiomyopathy Treatment Market

9. China Hypertrophic Cardiomyopathy Treatment Market

10. India Hypertrophic Cardiomyopathy Treatment Market

11. Japan Hypertrophic Cardiomyopathy Treatment Market

12. Australia Hypertrophic Cardiomyopathy Treatment Market

13. Indonesia Hypertrophic Cardiomyopathy Treatment Market

14. South Korea Hypertrophic Cardiomyopathy Treatment Market

15. Western Europe Hypertrophic Cardiomyopathy Treatment Market

16. UK Hypertrophic Cardiomyopathy Treatment Market

17. Germany Hypertrophic Cardiomyopathy Treatment Market

18. France Hypertrophic Cardiomyopathy Treatment Market

19. Italy Hypertrophic Cardiomyopathy Treatment Market

20. Spain Hypertrophic Cardiomyopathy Treatment Market

21. Eastern Europe Hypertrophic Cardiomyopathy Treatment Market

22. Russia Hypertrophic Cardiomyopathy Treatment Market

23. North America Hypertrophic Cardiomyopathy Treatment Market

24. USA Hypertrophic Cardiomyopathy Treatment Market

25. Canada Hypertrophic Cardiomyopathy Treatment Market

26. South America Hypertrophic Cardiomyopathy Treatment Market

27. Brazil Hypertrophic Cardiomyopathy Treatment Market

28. Middle East Hypertrophic Cardiomyopathy Treatment Market

29. Africa Hypertrophic Cardiomyopathy Treatment Market

30. Hypertrophic Cardiomyopathy Treatment Market Competitive Landscape And Company Profiles

31. Hypertrophic Cardiomyopathy Treatment Market Other Major And Innovative Companies

32. Global Hypertrophic Cardiomyopathy Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Hypertrophic Cardiomyopathy Treatment Market

34. Recent Developments In The Hypertrophic Cardiomyopathy Treatment Market

35. Hypertrophic Cardiomyopathy Treatment Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기